Progress in drug development for Alzheimer's disease: An overview in relation to mitochondrial energy metabolism
Language English Country France Media print-electronic
Document type Journal Article, Review
PubMed
27094132
DOI
10.1016/j.ejmech.2016.03.084
PII: S0223-5234(16)30266-5
Knihovny.cz E-resources
- Keywords
- Alzheimer's disease, Amyloid-beta binding alcohol dehydrogenase modulators, Cholinesterase inhibitors, Monoamine oxidase (MAO) inhibitors,
- MeSH
- Alzheimer Disease drug therapy metabolism pathology MeSH
- Energy Metabolism drug effects MeSH
- Monoamine Oxidase Inhibitors chemistry metabolism pharmacology therapeutic use MeSH
- Humans MeSH
- Mitochondria drug effects metabolism MeSH
- Drug Discovery methods MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Monoamine Oxidase Inhibitors MeSH
Current possibilities of Alzheimer's disease (AD) treatment are very limited and are based on administration of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and/or N-methyl-d-aspartate receptor antagonist, memantine. Newly synthesized drugs affect multiple AD pathophysiological pathways and can act as inhibitors of cholinesterases (AChE, BuChE), inhibitors of monoamine oxidases (MAO-A, MAO-B), modulators of mitochondrial permeability transition pores, modulators of amyloid-beta binding alcohol dehydrogenase and antioxidants. Effects of clinically used as well as newly developed AD drugs were studied in relation to energy metabolism and mitochondrial functions, including oxidative phosphorylation, activities of enzymes of citric acid cycle or electron transfer system, mitochondrial membrane potential, calcium homeostasis, production of reactive oxygen species and MAO activity.
References provided by Crossref.org
Acetylcholinesterase: The "Hub" for Neurodegenerative Diseases and Chemical Weapons Convention
